Genetic evolution of influenza viruses among selected countries in Latin America, 2017-2018.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 11 06 2019
accepted: 03 01 2020
entrez: 11 3 2020
pubmed: 11 3 2020
medline: 28 5 2020
Statut: epublish

Résumé

Since the 2009 influenza pandemic, Latin American (LA) countries have strengthened their influenza surveillance systems. We analyzed influenza genetic sequence data from the 2017 through 2018 Southern Hemisphere (SH) influenza season from selected LA countries, to map the availability of influenza genetic sequence data from, and to describe, the 2017 through 2018 SH influenza seasons in LA. We analyzed influenza A/H1pdm09, A/H3, B/Victoria and B/Yamagata hemagglutinin sequences from clinical samples from 12 National Influenza Centers (NICs) in ten countries (Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Paraguay, Peru and Uruguay) with a collection date from epidemiologic week (EW) 18, 2017 through EW 43, 2018. These sequences were generated by the NIC or the WHO Collaborating Center (CC) at the U.S Centers for Disease Control and Prevention, uploaded to the Global Initiative on Sharing All Influenza Data (GISAID) platform, and used for phylogenetic reconstruction. Influenza hemagglutinin sequences from the participating countries (A/H1pdm09 n = 326, A/H3 n = 636, B n = 433) were highly concordant with the genetic groups of the influenza vaccine-recommended viruses for influenza A/H1pdm09 and influenza B. For influenza A/H3, the concordance was variable. Considering the constant evolution of influenza viruses, high-quality surveillance data-specifically genetic sequence data, are important to allow public health decision makers to make informed decisions about prevention and control strategies, such as influenza vaccine composition. Countries that conduct influenza genetic sequencing for surveillance in LA should continue to work with the WHO CCs to produce high-quality genetic sequence data and upload those sequences to open-access databases.

Identifiants

pubmed: 32155152
doi: 10.1371/journal.pone.0227962
pii: PONE-D-19-16505
pmc: PMC7064222
doi:

Substances chimiques

Hemagglutinin Glycoproteins, Influenza Virus 0
Influenza Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0227962

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Vaccine. 2016 Sep 22;34(41):4905-4912
pubmed: 27577556
Nat Rev Microbiol. 2018 Jan;16(1):47-60
pubmed: 29081496
Vaccine. 2018 Jun 7;36(24):3555-3566
pubmed: 28648543
J Infect Dis. 2014 Jul 1;210(1):126-37
pubmed: 24446529
PLoS Pathog. 2017 Dec 28;13(12):e1006749
pubmed: 29284042
Pharmacoeconomics. 2018 Dec;36(12):1475-1490
pubmed: 30251078
Influenza Other Respir Viruses. 2016 May;10(3):170-5
pubmed: 26701079
Nature. 2015 Jul 9;523(7559):217-20
pubmed: 26053121
Med Ref Serv Q. 2019 Oct-Dec;38(4):358-368
pubmed: 31687905

Auteurs

Juliana Almeida Leite (JA)

Pan American Health Organization (PAHO/WHO), Washington, DC, United States of America.

Paola Resende (P)

Laboratorio de Virus Respiratorio, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.

Jenny Lara Araya (JL)

Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (INCIENSA), Tres Ríos, Cartago, Costa Rica.

Gisela Badillo Barrera (GB)

Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, Mexico, Mexico.

Elsa Baumeister (E)

Instituto Nacional de Enfermedades Infecciosas-Administración Nacional de Laboratorios e Institutos de Salud (INEI-ANLIS) "Dr. Carlos G. Malbran", Buenos Aires, Argentina.

Alfredo Bruno Caicedo (AB)

Instituto Nacional de Investigación en Salud Pública (INSPI), Guayaquil, Guayas, Ecuador.

Leticia Coppola (L)

Departamento de Laboratorio de Salud Publica (DLSP), Montevideo, Montevideo, Uruguay.

Wyller Alencar de Mello (WA)

Instituto Evandro Chagas (IEC), Ananindeua, Para, Brazil.

Domenica de Mora (D)

Instituto Nacional de Investigación en Salud Pública (INSPI), Guayaquil, Guayas, Ecuador.

Mirleide Cordeiro Dos Santos (M)

Instituto Evandro Chagas (IEC), Ananindeua, Para, Brazil.

Rodrigo Fasce (R)

Instituto de Salud Pública de Chile (ISPCH), Santiago, Santiago, Chile.

Jorge Fernández (J)

Instituto de Salud Pública de Chile (ISPCH), Santiago, Santiago, Chile.

Natalia Goñi (N)

Departamento de Laboratorio de Salud Publica (DLSP), Montevideo, Montevideo, Uruguay.

Irma López Martínez (IL)

Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, Mexico, Mexico.

Jannet Otárola Mayhua (JO)

Instituto Nacional de Salud (INS), Chorrillos, Lima, Peru.

Fernando Motta (F)

Laboratorio de Virus Respiratorio, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.

Maribel Carmen Huaringa Nuñez (MCH)

Instituto Nacional de Salud (INS), Chorrillos, Lima, Peru.

Jenny Ojeda (J)

Ministerio de Salud Pública, Quito, Pichincha, Ecuador.

María José Ortega (MJ)

Laboratorio Central de Salud Pública (LCSP), Ascuncion, Distrito Capital, Paraguay.

Erika Ospitia (E)

Instituto Nacional de Salud (INS), Bogota, Cundinamarca, Colombia.

Terezinha Maria de Paiva (TM)

Instituto Adolfo Lutz (IAL), Sao Paulo, Sao Paulo, Brazil.

Andrea Pontoriero (A)

Instituto Nacional de Enfermedades Infecciosas-Administración Nacional de Laboratorios e Institutos de Salud (INEI-ANLIS) "Dr. Carlos G. Malbran", Buenos Aires, Argentina.

Hebleen Brenes Porras (HB)

Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (INCIENSA), Tres Ríos, Cartago, Costa Rica.

Jose Alberto Diaz Quinonez (JAD)

Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Ciudad de México, Mexico, Mexico.
Division of Postgraduate Studies, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Viviana Ramas (V)

Departamento de Laboratorio de Salud Publica (DLSP), Montevideo, Montevideo, Uruguay.

Juliana Barbosa Ramírez (JB)

Instituto Nacional de Salud (INS), Bogota, Cundinamarca, Colombia.

Katia Correa de Oliveira Santos (KCO)

Instituto Adolfo Lutz (IAL), Sao Paulo, Sao Paulo, Brazil.

Marilda Mendonça Siqueira (MM)

Laboratorio de Virus Respiratorio, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.

Cynthia Vàzquez (C)

Laboratorio Central de Salud Pública (LCSP), Ascuncion, Distrito Capital, Paraguay.

Rakhee Palekar (R)

Pan American Health Organization (PAHO/WHO), Washington, DC, United States of America.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH